Clarithromycin-amoxycillin-containing triple therapy: A valid empirical first-line treatment for helicobacter pylori eradication in Hong Kong?

Helicobacter

Volumn 14, Issue 6, 2009, Pages 505-511

  Hung, Ivan F N ^a   Chan, Pierre ^a   Leung, Sally ^a   Chan, Fion S Y ^a   Hsu, Axel ^a   But, David ^a   Seto, Wai Kay ^a   Wong, Siu Yin ^a   Chan, Chi Kuen ^a   Gu, Qing ^a   Tong, Teresa S M ^a   Cheung, Ting Kin ^a   Chu, Kent Man ^a   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clarithromycin; Empirical first line eradication; Helicobacter pylori; Hong Kong; Levofloxacin

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; RADIOISOTOPE; UNCLASSIFIED DRUG; UREA C 14;

ADULT; ANOREXIA; ARTICLE; BACTERIUM ISOLATE; BLOATING; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; ERADICATION THERAPY; FEMALE; HEADACHE; HEART PALPITATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HONG KONG; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALAISE; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT DURATION; TREATMENT FAILURE; UREA BREATH TEST; XEROSTOMIA;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HONG KONG; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; OMEPRAZOLE;

HELICOBACTER PYLORI;

EID: 70449401522     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00722.x     Document Type: Article

References (31)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984 1 : 1311 1315.
2. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC 1994 61 : 1 241.
3. Chey CD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 1825.
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
5. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998 13 : 1 12.
6. Graham DY, Akiko S. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008 6 : 321 331.
7. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period. J Antimicrob Chemother 2007 59 : 783 785. (Pubitemid 47073419)
8. Nista EC, Candelli M, Zocco M, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006 101 : 1985 1990.
9. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007 26 : 495 500.
10. Lee CC, Lee VW, Chan FK, et al. Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008 54 : 50 3.
11. Bogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006 11 : 441 445.
12. Wong BCY, Wong WM, Wang WH, et al. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese: the best tests for routine clinical use and research purposes. Aliment Pharmacol Ther 2001 15 : 505 511.
13. 13C-urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2000 14 : 1353 1358.
14. Osata MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001 161 : 1217 1220. (Pubitemid 32691518)
15. Gu Q, Xia HH, Wang JD, et al. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion 2006 73 : 101 106.
16. 450 2C19 poor metabolizers. J Gastroenterol 1999 34 (Suppl. 11 80 3.
17. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Cin Pharmacol Ther 2006 44 : 297 302.
18. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006 11 : 39 45.
19. Kim JM, Kim JS, Kim N, et al. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006 28 : 6 13.
20. Hung KH, Sheu BS, Chang WL, et al. Prevalence of primary fluoroquinolone resistance among clinic isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009 14 : 61 5.
21. Carothers JJ, Bruce MG, Hennessy TW, et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007 44 : e5 8.
22. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004 10 : 1088 1094.
23. Yee YK, Cheung TK, Chu KM, et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007 26 : 1063 1067.
24. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006 101 : 488 496.
25. Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006 11 : 243 249.
26. Ma J, Zeng Z, Chen Z, et al. High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6′)-lb-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food producing animals. Antimicrob Agents Chemother 2009 53 : 519 524.
27. Hosaka Y, Irinoda K, Nakano R, et al. Antibacterial activity of 16 antibiotics against Helicobacter pylori. Jpn J Antibiot 2000 53 : 623 630.
28. Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007 29 : 389 396.
29. Kim JM, Kim JS, Kim N, et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005 56 : 965 967.
30. Ho PL, Que TL, Chiu SS, et al. Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001. Emerg Infect Dis 2004 10 : 1250 1257.
31. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009 7 : 145 148.